Abiraterone Accord Europäische Union - Deutsch - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Zytiga Tabletten Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

zytiga tabletten

janssen-cilag ag - abirateronum - tabletten - abirateroni acetas 250 mg corresp. abirateronum 223 mg, lactosum monohydricum corresp. lactosum 188.72 mg, cellulosum microcristallinum, carmellosum natricum conexum et natrii laurilsulfas corresp. natrium 5.38 mg, povidonum k 29-32, silica colloidalis anhydrica, magnesii stearas, pro compresso. - prostatakarzinom - synthetika

Zytiga 500 mg Filmtabletten Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

zytiga 500 mg filmtabletten

janssen-cilag ag - abirateronum - filmtabletten - abirateroni acetas 500 mg corresp. abirateronum 446 mg, lactosum monohydricum corresp. lactosum 240.5 mg, carmellosum natricum conexum et natrii laurilsulfas corresp. natrium 10.42 mg, hypromellosum, cellulosum microcristallinum silicificatum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - prostatakarzinom - synthetika